Latest news with #ProfitAfterTax
Yahoo
6 days ago
- Business
- Yahoo
Pro Medicus Ltd (PMCUF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Wins
Revenue Growth: Up just under 32%. Profit After Tax: Increased by approximately 40%. Underlying EBIT: Around 40% growth. Margins: Increased from mid-72% to 74%. Retained Earnings: Increased by about 36%. Dividend: Fully franked dividend of $0.30 per share, up 37.5%. Contract Wins: Seven contracts totaling $520 million. Contract Renewals: Two large contracts worth $130 million. Product Upgrades: Additional products with existing clients totaling $39 million. Forward Revenue: Increased from low $600 million to $948 million over a five-year window. Australian Business Growth: Grew just under 5%. Total Addressable Market (TAM): Updated to $670 million. Current Market Penetration: Estimated at about 10% and growing. Warning! GuruFocus has detected 5 Warning Signs with PMCUF. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Pro Medicus Ltd (PMCUF) reported a significant increase in key financial metrics, with revenue up nearly 32% and profit after tax up approximately 40%. The company secured seven new contracts totaling $520 million and renewed two large contracts worth $130 million, indicating strong sales performance. Pro Medicus Ltd (PMCUF) has maintained industry-leading margins, increasing from mid-72% to 74%, showcasing efficient cost management. The company has expanded its product portfolio with successful implementations of Visage 7 and Open Archive, transitioning clients from on-premise to cloud solutions. Pro Medicus Ltd (PMCUF) has made significant strides in AI and research collaborations, including agreements with UCSF, Mayo, and NYU, positioning itself for future growth in AI-driven healthcare solutions. Negative Points The pathology market is still emerging, and Pro Medicus Ltd (PMCUF) has not yet determined pricing for pathology exams, which could impact future revenue streams. The company faces competition from legacy systems and other vendors, with 90% of the market still using older technologies. There is uncertainty regarding the adoption rate of digital pathology, as the market is nascent and institutions are only beginning to consider digital solutions. Pro Medicus Ltd (PMCUF) has not yet penetrated the Chinese market due to regulatory and market dynamics, limiting its global expansion potential. The company acknowledges that it does not have a 100% hit rate on pipeline contracts, with some losses attributed to price competition and perceived cost. Q & A Highlights Q: Can you clarify the market size for the pathology product and how it compares to radiology? A: The pathology market is where radiology was about 20 years ago. It's slightly different because the bulk of pathology isn't image-based. The market size is a bit less than radiology, and it's still emerging. We believe our technology is well-suited for this expanding market, particularly with cloud storage capabilities. Q: How do you plan to maintain your technological leadership in AI given the democratization of software development? A: There are two streams of AI in our space: generative AI, which aids in reporting, and clinical AI, which requires rigorous validation. The clinical part still has significant barriers to entry, such as FDA clearance, which maintains our competitive edge. Q: What is the addressable market for cardiology, and how does it compare to radiology? A: Cardiology can be between 15% and 20% of radiology by value, depending on the organization. There are fewer tests, but each is more expensive. We expect to sell cardiology solutions back to existing clients and offer them to new clients as part of a full stack. Q: How is the revenue from an Open Archive upgrade like NYU's structured compared to a new full stack customer? A: Revenue from data migration is taken upfront based on milestones, while exam revenue is spread evenly over the contract period. For NYU, 10% to 15% of the total contract value is from data migration. Q: What are your thoughts on the competitive landscape, especially regarding cloud and AI? A: We believe we are the only company offering true cloud solutions at scale. While many competitors claim to have cloud and AI capabilities, we haven't seen any that match our level of implementation and scalability. Q: Can you discuss the potential for pathology adoption and the initial client reactions? A: The initial reaction to our pathology product has been positive, though it's early days. The large data sets in pathology align well with our strengths in cloud storage and streaming technology. We expect adoption to grow as institutions increasingly consider digital pathology. Q: What is the status of your contract renewals, and have you started discussions? A: We have started discussions for renewals, and they are proceeding similarly to past renewals. Some larger clients prefer to start conversations earlier, but the cadence varies by client. Q: How do you view the opportunity in Germany and Asia compared to the US? A: The US remains our primary market due to its size and fewer barriers to business. Europe and Asia present opportunities, particularly as cloud adoption increases, but the cost of sale is higher, and opportunities are smaller compared to the US. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
Pro Medicus Ltd (PMCUF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Wins
Revenue Growth: Up just under 32%. Profit After Tax: Increased by approximately 40%. Underlying EBIT: Around 40% growth. Margins: Increased from mid-72% to 74%. Retained Earnings: Increased by about 36%. Dividend: Fully franked dividend of $0.30 per share, up 37.5%. Contract Wins: Seven contracts totaling $520 million. Contract Renewals: Two large contracts worth $130 million. Product Upgrades: Additional products with existing clients totaling $39 million. Forward Revenue: Increased from low $600 million to $948 million over a five-year window. Australian Business Growth: Grew just under 5%. Total Addressable Market (TAM): Updated to $670 million. Current Market Penetration: Estimated at about 10% and growing. Warning! GuruFocus has detected 5 Warning Signs with PMCUF. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Pro Medicus Ltd (PMCUF) reported a significant increase in key financial metrics, with revenue up nearly 32% and profit after tax up approximately 40%. The company secured seven new contracts totaling $520 million and renewed two large contracts worth $130 million, indicating strong sales performance. Pro Medicus Ltd (PMCUF) has maintained industry-leading margins, increasing from mid-72% to 74%, showcasing efficient cost management. The company has expanded its product portfolio with successful implementations of Visage 7 and Open Archive, transitioning clients from on-premise to cloud solutions. Pro Medicus Ltd (PMCUF) has made significant strides in AI and research collaborations, including agreements with UCSF, Mayo, and NYU, positioning itself for future growth in AI-driven healthcare solutions. Negative Points The pathology market is still emerging, and Pro Medicus Ltd (PMCUF) has not yet determined pricing for pathology exams, which could impact future revenue streams. The company faces competition from legacy systems and other vendors, with 90% of the market still using older technologies. There is uncertainty regarding the adoption rate of digital pathology, as the market is nascent and institutions are only beginning to consider digital solutions. Pro Medicus Ltd (PMCUF) has not yet penetrated the Chinese market due to regulatory and market dynamics, limiting its global expansion potential. The company acknowledges that it does not have a 100% hit rate on pipeline contracts, with some losses attributed to price competition and perceived cost. Q & A Highlights Q: Can you clarify the market size for the pathology product and how it compares to radiology? A: The pathology market is where radiology was about 20 years ago. It's slightly different because the bulk of pathology isn't image-based. The market size is a bit less than radiology, and it's still emerging. We believe our technology is well-suited for this expanding market, particularly with cloud storage capabilities. Q: How do you plan to maintain your technological leadership in AI given the democratization of software development? A: There are two streams of AI in our space: generative AI, which aids in reporting, and clinical AI, which requires rigorous validation. The clinical part still has significant barriers to entry, such as FDA clearance, which maintains our competitive edge. Q: What is the addressable market for cardiology, and how does it compare to radiology? A: Cardiology can be between 15% and 20% of radiology by value, depending on the organization. There are fewer tests, but each is more expensive. We expect to sell cardiology solutions back to existing clients and offer them to new clients as part of a full stack. Q: How is the revenue from an Open Archive upgrade like NYU's structured compared to a new full stack customer? A: Revenue from data migration is taken upfront based on milestones, while exam revenue is spread evenly over the contract period. For NYU, 10% to 15% of the total contract value is from data migration. Q: What are your thoughts on the competitive landscape, especially regarding cloud and AI? A: We believe we are the only company offering true cloud solutions at scale. While many competitors claim to have cloud and AI capabilities, we haven't seen any that match our level of implementation and scalability. Q: Can you discuss the potential for pathology adoption and the initial client reactions? A: The initial reaction to our pathology product has been positive, though it's early days. The large data sets in pathology align well with our strengths in cloud storage and streaming technology. We expect adoption to grow as institutions increasingly consider digital pathology. Q: What is the status of your contract renewals, and have you started discussions? A: We have started discussions for renewals, and they are proceeding similarly to past renewals. Some larger clients prefer to start conversations earlier, but the cadence varies by client. Q: How do you view the opportunity in Germany and Asia compared to the US? A: The US remains our primary market due to its size and fewer barriers to business. Europe and Asia present opportunities, particularly as cloud adoption increases, but the cost of sale is higher, and opportunities are smaller compared to the US. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
08-08-2025
- Business
- Zawya
Dubai Electricity and Water Authority PJSC reports a record AED14.6bln in revenue for the first half of 2025 and approves dividend payment of AED3.1bln
H1 Profit After Tax Hits AED 2.9 billion (up 13.2% YoY) H1 Operating Cash Flow Surges to AED 9.2 billion (up 61.3% YoY) Q2 2025 Profit After Tax Jumps to AED 2.4 billion (up 25.8% YoY) The Board approved payment of AED 3.1 billion in dividends in October 2025 for H1, 2025. Dubai, UAE: Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai's exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its first half 2025 consolidated financial results, recording first half revenue of AED 14.6 billion, EBITDA of AED 7.0 billion, operating profit of AED 3.7 billion, net profit of AED 2.9 billion and cash from operations of AED 9.2 billion. Quote 'DEWA is committed to be an innovative and sustainable corporation inspired by the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister and Minister of Defence, and Chairman of The Executive Council of Dubai, and His Highness Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, First Deputy Ruler of Dubai, Deputy Prime Minister and Minister of Finance. Under their guidance, we are progressing in our journey towards Net Zero Carbon by 2050 and will continue to play a decisive role in Dubai's rapid progress,' said HE Saeed Mohammed Al Tayer, Vice Chairman and MD & CEO of DEWA. 'We are proud to report DEWA's strongest-ever financial results for both the 2nd quarter and first half of 2025 - a reflection of disciplined execution, growing demand, and our commitment to operational excellence. In H1 2025, we achieved AED 14.6 billion in revenue, AED 7.0 billion in EBITDA, and AED 2.9 billion in net profit - marking growth of 6.9%, 5.3%, and 13.2% respectively. Operating cash flow reached a record AED 9.2 billion, up 61.3% year-on-year. Also, we approved a dividend of AED 3.1 billion for H1, 2025, which is payable in October, 2025. To date we have invested over AED 230 billion in state-of-the-art infrastructure. Our results demonstrate the resilience of our model and the ability to generate strong returns while advancing Dubai's sustainable development. Looking ahead, we expect consistent value creation for our stakeholders, supported by Dubai's economic growth, our robust business model and our sector leading operational benchmarks that are acknowledged to be No 1 globally.' added Al Tayer. Financial performance summary DEWA delivered a record financial and operational performance for the six months ended 30 June 2025. Revenue rose by 6.9% year-on-year to AED 14.6 billion, driven by continued growth in electricity and water demand, as well as steady expansion in district cooling through Empower. EBITDA increased by 5.3% to AED 7.0 billion, supported by improved operating efficiencies and effective cost control across core segments, highlighting the Group's strong underlying profitability. Net profit for the period grew 13.2% to AED 2.90 billion, reflecting higher operating income, and decline in net finance costs by 15.45% compared to the same period in the previous year. Capital expenditure during the period totalled AED 4.6 billion, covering investment in generation capacity, transmission networks and district cooling infrastructure. DEWA expects stronger revenue and profit contribution in the second half of the year, considering the seasonal pattern of our business. The Group remains focused on delivering long-term growth through strategic investments in clean energy, digital infrastructure, and water desalination, in alignment with Dubai's Green Economy vision. DEWA continues to demonstrate financial resilience, operational excellence, and consistent value creation for its stakeholders. Operating performance summary In the second quarter of 2025, DEWA's total energy generation Including Energy import from IPPs soared to a high of 16.9 TWh marking a 10.88% increase from the 15.3 TWh recorded during the second quarter of 2024. Notably, DEWA generated 3.3 TWh of clean energy during the quarter. This clean energy accounted for 19.46% of the total energy generated in Q2, 2025. DEWA is committed to using clean energy to maintain a sustainable generation mix to meet the consistently growing demand. In addition, DEWA delivered 2.18 TWh from Hassyan power plant and 11.46 TWh from its remaining generation portfolio during the second quarter of 2025. DEWA experienced a 2.95% increase in its quarterly peak power demand compared to Q2, 2024, reaching 10.545 GW. The quarterly gross heat rate of 7,693 BTU/kWh achieved, represents a stellar 7.01% improvement over the same period from the previous year. Collectively, these achievements highlight the company's unwavering commitment to delivering operational excellence while facing very strong top line demand. DEWA's total desalinated water production in the second quarter of 2025 grew by 9.55% compared to the previous year, reaching a record of 40.78 billion Imperial Gallons (BIG). The peak daily desalinated water demand reached 475 MIG which is a 5.87% increase over the same period of the previous year. At the end of the second quarter of 2025, DEWA served 1,292,487 customer accounts, representing a 4.81% increase in customer accounts from the same period in the last year. Select quarterly highlights In the second quarter of 2025, DEWA commissioned two 132 kV substations, and four hundred and eighty three 11kV substations. By the end of the first half of 2025, the company's system installed generation capacity reached 17.979 GW with 3.860 GW of this capacity representing renewable energy. The company's installed desalinated water production capacity was 495 MIGD. By the end of 2030, DEWA plans to have total installed power generation capacity of 22 GW and 735 MIGD of desalinated water. Of this 22 GW, around 7.5 GW will be from renewable sources, representing 34% and out of 735 MIGD water production capacity, 308 MIGD will be using reverse osmosis technology utilizing renewable energy. Corporate Actions: Dividends & Dividend policy As per DEWA's dividend policy, the Company expects to pay a minimum annual dividend of AED 6.2 billion in the first five years starting October 2022. The dividends are paid semi-annually in April and October. On 10th April 2025, DEWA distributed AED 3.1 billion as dividend for H2, 2024 to its shareholders, based on a record date of 3rd April 2025. For H1, 2025, DEWA has sought and received approvals to distribute AED 3.1 billion to its shareholders based on a record date of 17th October, 2025. Audited Financials DEWA's audited financials can be found at DEWA's website: or on DFM's website About Dubai Electricity and Water Authority PJSC DEWA was created in 1992 as a result of the merger of the Dubai Electricity Company and the Dubai Water Department. DEWA is the exclusive electricity and water utility provider in Dubai. DEWA was listed on the Dubai Financial Market in April 2022. DEWA's attractive business profile, as viewed by investors, has led to the historic success of this public listing that attracted US$ 85 billion demand and 37 times oversubscription. The Group generates, transmits and distributes electricity and potable water to end users throughout Dubai. DEWA owns 56% of Empower, currently the world's largest district cooling services provider by connected capacity, and owns, manages, operates and maintains district cooling plants and affiliated distribution networks across Dubai. The Group also comprises several other businesses including Mai Dubai, a manufacturer and distributor of bottled water, Digital DEWA, a digital business solutions company, and Etihad ESCO, a company focused on the development and implementation of energy efficient solutions.
Yahoo
04-08-2025
- Business
- Yahoo
Symphony Ltd (BOM:517385) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Revenue (Standalone): INR229 crores, down from INR373 crores. Profit After Tax (PAT) (Standalone): INR37 crores, down from INR69 crores. Interim Dividend: INR1 per share, totaling INR7 crores. Revenue (Trailing 12 Months, Standalone): INR1,038 crores, up from INR996 crores. EBITDA (Trailing 12 Months, Standalone): INR229 crores, almost flat. Profit Before Tax (PBT) Before Exceptional Item (Trailing 12 Months, Standalone): INR283 crores, up from INR275 crores. Return on Capital Employed (ROCE): Infinite due to negative capital employed. Return on Net Worth: 18%. Treasury: INR363 crores as of 30th June. Consolidated Revenue (Continuing Operations): INR251 crores. Consolidated PAT (Continuing Operations): INR39 crores. PAT Margin (Continuing Operations): 15.40%. Sales (IMPCO Mexico and Symphony AU): INR99 crores. PAT (IMPCO Mexico and Symphony AU): INR3 crores. EBITDA Margin (IMPCO Mexico and Symphony AU): 12%. IPR Transaction Value: USD 5.2 million (INR44 crores). Loan Repayment by GSK China: INR28 crores repaid, outstanding loan INR26 crores. New Product Launch: Air Force range of air coolers. Non-Household Air Cooler Products Contribution: More than 25% of sales in Symphony India. Warning! GuruFocus has detected 1 Warning Sign with BOM:517385. Release Date: August 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Symphony Ltd (BOM:517385) reported the second highest ever June quarter sales, surpassing previous records despite a challenging summer. The company declared an interim dividend of INR1 per share and a final dividend of INR8 per share, reflecting strong shareholder returns. GSK China continues to show strong growth momentum, contributing positively to the consolidated financials. The company's new product categories, such as tower fans and kitchen cooling fans, have shown robust growth, contributing significantly to the revenue. Symphony Ltd (BOM:517385) has successfully implemented an asset-light business model in Australia, which is expected to improve profitability. Negative Points The company's revenue and profit after tax (PAT) declined significantly due to a subdued summer, with revenue dropping from INR373 crores to INR229 crores. High channel inventory levels due to aggressive pre-season stocking and a weak summer could impact future sales. The IMPCO Mexico and Symphony AU subsidiaries reported lower EBITDA margins due to operating leverage challenges. The divestiture process for IMPCO Mexico and Symphony AU is still in early stages, creating uncertainty about the timeline for monetization. The company faces challenges in the South region of India, where the summer was particularly weak, affecting sales. Q & A Highlights Q: What is the current status of channel inventory, and how does it compare to expectations? A: The channel inventory is higher than expected due to aggressive inventory placement until March and a subdued summer. Exact numbers are not available, but it is more than normal. This situation is part of the business cycle, and Symphony has experienced similar conditions in the past. - Nrupesh Shah, Managing Director - Corporate Affairs Q: How are the adjacent categories like tower fans and water heaters performing, and what is their growth outlook? A: These categories have shown a 50%+ CAGR over the last 3-4 years and continue to grow at a faster rate than the core residential coolers. They have become a significant part of the growth portfolio, contributing to a more robust and contra-seasonal product mix. - Amit Kumar, Group CEO and Executive Director Q: What is the adoption rate of BLDC technology in coolers and tower fans, and how does Symphony differentiate itself from competitors? A: The BLDC range is priced at a 10-15% premium over standard products. Adoption is better in tower fans than in air coolers. Unlike other brands, Symphony maintains profitability despite top-line growth in BLDC products. - Amit Kumar, Group CEO and Executive Director Q: How does Symphony plan to scale up its portfolio in exports and non-air cooler products, and what are the specific initiatives? A: Symphony is expanding its market presence in industrial coolers, tower fans, and kitchen cooling fans, which have shown impressive growth. Water heaters are being rolled out gradually across more cities. Exports are also performing well, contributing to Symphony's growth beyond domestic sales. - Achal Bakeri, Executive Chairman and Managing Director Q: What is the impact of tariffs on Symphony's export plans, particularly to the US? A: The US tariffs are an evolving situation, but currently, tariffs on products from India are lower than those from China. Symphony is not overly concerned about tariffs affecting its plans, as the focus is on the summer of '26. Current sales in the US have increased significantly compared to the previous year. - Achal Bakeri, Executive Chairman and Managing Director For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
29-07-2025
- Business
- Yahoo
Nippon Life India Asset Management Ltd (BOM:540767) Q1 2026 Earnings Call Highlights: Record ...
Operating Profit: INR3.78 billion, highest ever quarterly operating profit. Profit After Tax: INR3.96 billion, up 19% YoY and 33% QoQ. Revenue: INR6.07 billion, up 20% YoY and 7% QoQ. Other Income: INR1.46 billion, up 12% YoY and 5.3x QoQ. Operating Expenses: INR2.29 billion, up 16% YoY and 8% QoQ. Total Assets Under Management (AUM): INR7.44 trillion. Mutual Fund Quarterly Average AUM: INR6.13 billion, up 27% YoY and 10% QoQ. Market Share: Increased 23 basis points QoQ to 8.49%. SIP Contribution: INR806 billion, up 29% YoY and 3% QoQ. ETF AUM: INR1.74 trillion, with a market share of 19.76%. Digital Purchase Transactions: 3.57 million in Q1 FY26, up 27% YoY. Offshore AUM: INR166 billion, up 10% YoY. Warning! GuruFocus has detected 5 Warning Signs with RVTY. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Nippon Life India Asset Management Ltd (BOM:540767) achieved its highest ever quarterly operating profit at INR3.78 billion and profit after tax at INR3.96 billion. The company was the fastest-growing AMC among the top 10 AMCs on both a quarter-on-quarter and year-on-year basis. Market share increased to 8.49%, the highest since June 2019, with significant gains in equity net sales and SIP market share. The company launched four new products in Q1 FY26, expanding its offerings in the passive fund segment. Digital purchase transactions rose by 27% YoY, with digital business contributing 75% of total new purchase transactions in Q1 FY26. Negative Points Systematic folio numbers declined sequentially due to a one-time cleanup of inactive SIPs, impacting the numerator. There is a potential for a 2 to 3 basis point decline in yields annually due to telescopic pricing and higher costs for new flows. The ESOP cost for the year is expected to be around INR46 crores, with a potential increase in the remaining quarters. The company's equity AUM share decreased by 0.3% quarter-on-quarter to 46.9% for Q1 FY26. There is uncertainty regarding the impact of new regulatory proposals on scheme sizes and TER, which could affect future strategy. Q & A Highlights Q: Can you provide details on the yields for different segments this quarter and any commentary on ESOP costs? A: The blended yield for the current quarter is 36 basis points, with equity yield at 55 basis points, debt at 25 basis points, liquid at 12 basis points, and ETF at 17 basis points. The ESOP cost for the year is expected to be around INR46 crores, with the current quarter's cost at INR11 crores. Q: Why has the systematic folio declined sequentially, and is this cleanup a regular activity? A: The decline was due to a one-time cleanup of inactive SIPs across the industry, which was not specific to any month or AMC. This was a large-scale cleanup, and while it might be revisited in 6 to 12 months, it is currently considered a one-time activity. Q: What is the rationale behind launching new passive funds, and how have they performed? A: We focus on unique ideas in the market, and our recent passive fund launches have seen interest. We do not target specific volumes for these funds, but they build up over time as investors flow into these passive ideas. Our MNC fund, launched in July, received a good response. Q: Can you explain the impact of the new AMC discussion paper on scheme size and TER? A: The proposal suggests launching new schemes if the existing scheme size exceeds INR50,000 crores, allowing the new scheme to charge a TER equivalent to the old scheme. While we await final guidelines, we do not see any negatives and anticipate potential marginal positives. Q: Is there a change in customer behavior or distributor preferences in recent months? A: There hasn't been a significant change in the last six months, but over the years, investors have matured, reacting less to market volatility. Brand comfort and service experience are increasingly important alongside performance, influencing investor and distributor decisions. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
